SPOTLIGHT -
Slideshow
Author(s):
Once thought untreatable, we now have two FDA-approved medications for TD and a handful of off-label options. More in this research update.
New Ingrezza Data Demonstrates Functional and Quality of Life Improvements in Patients With Tardive Dyskinesia
Not All That Writhes Is Tardive Dyskinesia
Phase 1 Study Initiated: NBI-1140675 for Neurological and Neuropsychiatric Conditions
Significant Improvements in Functionality and Quality of Life: New Data on Ingrezza for Tardive Dyskinesia
Psychopharmacology Innovations
Deutetrabenazine Shows Long Term Efficacy and Safety in Patients with Tardive Dyskinesia